Steinert Jessica Marie, Seifert Roland
Institute of Pharmacology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany.
Naunyn Schmiedebergs Arch Pharmacol. 2025 Jun 7. doi: 10.1007/s00210-025-04260-2.
The Schmiedeberg Medal, awarded by the German Society for Experimental and Clinical Pharmacology and Toxicology (DGPT), is the highest honour for excellent pharmacologists and has been awarded to 47 recipients until 2024. The first medal was awarded to Wolfgang Heubner in 1956, the most recent of our analysis to Franz Hofmann in June 2024. This is the first profound analysis of the prize winners: Most of the prize winners (63.83%) were born in Germany, and more than half (53.19%) came from academic families. Notably, only two women (4.26%), Edith Bülbring and Marthe Vogt, have received the award, although the presence of women in medicine and among members of the DGPT is on the rise. Almost 90% of the award winners studied medicine, and 29.79% spent part of their studies in Berlin. The award winners enjoyed exceptional quality of life and consistently surpassed the average life expectancy, with an average age of 86.26 years. On average, their careers spanned 50.65 years, with the Schmiedeberg Medal being awarded 20.74 years after the peak of their careers. Over time, the number of publications and productivity, co-authors, and senior authorships increased, while first authorships decreased. This shift reflects the growing importance of collaborative scientific work as opposed to solo endeavours. The overall publication productivity also increased during the observation period, with the Naunyn-Schmiedeberg's Archives of Pharmacology being the most prominent journal for these publications, although its influence decreased over time. The predominant language of publication was English, accounting for 72.28% of the articles, a trend that has increasingly replaced German since the 1970s. The most common research focus was the cholinergic and adrenergic systems. Thus, Schmiedeberg Medal recipients are an outstandingly productive group of scientists enjoying a long scientific career and a long high-quality life. In addition, Schmiedeberg Medal recipients encountered numerous societal and scientific challenges which they mastered excellently. The gender gap for this award is dramatic, reflecting the very low number of eligible female pharmacologists for this award.
施米德贝格奖章由德国实验与临床药理学及毒理学协会（DGPT）颁发，是授予杰出药理学家的最高荣誉，截至2024年已授予47位获奖者。第一枚奖章于1956年授予沃尔夫冈·霍伊布纳，我们分析的最近一位获奖者是2024年6月的弗朗茨·霍夫曼。这是对获奖者的首次深入分析：大多数获奖者（63.83%）出生于德国，超过一半（53.19%）来自学术家庭。值得注意的是，只有两位女性（4.26%），即伊迪丝·比尔布林和玛尔特·沃格特获得过该奖项，尽管医学领域以及DGPT成员中的女性人数在增加。近90%的获奖者学习医学，29.79%的人曾在柏林学习过一段时间。获奖者享有卓越的生活质量，寿命始终超过平均预期寿命，平均年龄为86.26岁。他们的职业生涯平均长达50.65年，施米德贝格奖章在其职业生涯巅峰期过后20.74年颁发。随着时间的推移，出版物数量、产出、共同作者数量和资深作者身份有所增加，而第一作者身份则减少。这种转变反映出合作性科学工作相对于个人努力的重要性日益增加。在观察期内，总体出版物产出也有所增加，《瑙恩-施米德贝格药理学文献》是这些出版物最著名的期刊，尽管其影响力随时间有所下降。出版物的主要语言是英语，占文章的72.28%，自20世纪70年代以来这一趋势日益取代德语。最常见的研究重点是胆碱能和肾上腺素能系统。因此，施米德贝格奖章获得者是一群极具生产力的科学家，拥有漫长的科学职业生涯和高质量的长寿生活。此外，施米德贝格奖章获得者还面临众多社会和科学挑战，他们出色地应对了这些挑战。该奖项的性别差距巨大，反映出符合该奖项条件的女性药理学家数量极少。
